Survival and Prognostic Factors for Hepatocellular Carcinoma: an Egyptian Multidisciplinary Clinic Experience |
Abdelaziz, Ashraf Omar
(Department Endemic Hepatogastroenterology, National Cancer Institute, Cairo University)
Elbaz, Tamer Mahmoud (Department Endemic Hepatogastroenterology, National Cancer Institute, Cairo University) Shousha, Hend Ibrahim (Department Endemic Hepatogastroenterology, National Cancer Institute, Cairo University) Ibrahim, Mostafa Mohamed (Department Endemic Hepatogastroenterology, National Cancer Institute, Cairo University) El-Shazli, Mostafa Abdel Rahman (Department General Surgery, National Cancer Institute, Cairo University) Abdelmaksoud, Ahmed Hosni (Department Diagnostic and Interventional Radiology, National Cancer Institute, Cairo University) Aziz, Omar Abdel (Department Diagnostic and Interventional Radiology, National Cancer Institute, Cairo University) Zaki, Hisham Atef (Department Clinical Oncology, National Cancer Institute, Cairo University) Elattar, Inas Anwar (Department Biostatistics and Cancer Epidemiology, National Cancer Institute, Cairo University) Nabeel, Mohamed Mahmoud (Department Endemic Hepatogastroenterology, National Cancer Institute, Cairo University) |
1 | The Egyptian Guidelines for Management of Hepatocellular Carcinoma by Egyptian Society of Liver Cancer. First edition (2011). In: www.egslc.com/content/Guidlines.pdf |
2 | Raza SA, Clifford GM, Franceschi S (2007). Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br J Cancer, 96, 1127-34. DOI ScienceOn |
3 | Takayasu K, Arii S, Ikai I, et al (2006). Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology, 131, 461-9. DOI ScienceOn |
4 | Tandon P, Garcia-Tsao G (2009). Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int, 29, 502-10. DOI ScienceOn |
5 | World Health Organization (2010). Mortality database. IARC. Available from: http://www-dep.iarc.fr/WHOdb/WHOdb.htm |
6 | Xu J, Liu C, Zhou L, et al (2012). Distinctions between clinicopathological factors and prognosis of alpha-fetoprotein negative and positive hepatocelluar carcinoma patients. Asian Pac J Cancer Prev, 13, 559-62. 과학기술학회마을 DOI ScienceOn |
7 | Lerose R, Molinari R, Rocchi E, Manenti F, Villa E (2001). Prognostic features and survival of hepatocellular carcinoma in Italy: impact of stage of disease. Eur J Cancer, 37, 239-45. DOI ScienceOn |
8 | Khattab MA, Eslam M, Sharwae MA, Hamdy L (2010) Seroprevalence of hepatitis C and B among blood donors in Egypt: Minya Governorate, 2000-2008. Am J Infect Control, 38, 640-1. DOI ScienceOn |
9 | Kirchner G, Kirovski G, Hebestreit A, et al (2010). Epidemiology and survival of patients with hepatocellular carcinoma in Southern Germany. Int J Clin Exp Med, 3, 169-79. |
10 | Lee SS, Shin HS, Kim HJ, et al (2012). Analysis of prognostic factors and 5-year survival rate in patients with hepatocellular carcinoma: a single-center experience. Korean J Hepatol, 18, 48-55. DOI ScienceOn |
11 | Llovet JM, Bru C, Bruix J (1999). Prognosis of hepatocellular carcinoma:the BCLC staging classification. Semin Liver Dis, 19, 329-38. DOI ScienceOn |
12 | Op den Winkel M, Nagel D, Sappl J, et al (2012). Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. PLoS One, 7, 45066. DOI |
13 | Llovet JM, Bustamante J, Castells A, et al (1999). Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology, 29, 62-7. DOI ScienceOn |
14 | National Cancer Registry of Egypt (2010). Magnitude of hepatocellular carcinoma in Egypt. Available from: http://www.nci.cu.edu.eg/ |
15 | Norsa'adah B, Nurhazalini-Zayani CG (2013). Epidemiology and survival of hepatocellular carcinoma in north-east Peninsular Malaysia. Asian Pac J Cancer Prev, 14, 6955-9. 과학기술학회마을 DOI ScienceOn |
16 | Park JW (2002). National policy of early detection in hepatocellular carcinoma. Korean J Hepatol, 8, 16-9. |
17 | Ezzat S, Abdel-Hamid M, Eissa SA, et al (2005). Associations of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt. Int J Hyg Environ Health, 208, 329-39. DOI ScienceOn |
18 | Elbaz T, Kassas M, Esmat G (2013). Management of Hepatocellular Carcinoma: Updated Review. J Cancer Therapy, 4, 536-45. DOI |
19 | El-Serag HB, Siegel AB, Davila JA, et al (2006). Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol, 44, 158-66. DOI ScienceOn |
20 | Esmat G, Elbaz T, Kassas M (2013). Hepatocellular carcinoma in Egypt: An updated status. Liver Cancer: Act today, save your life tomorrow. World Gastroenterology Organisation (WGO). WDHD 2013 Final Publication. www.wgofoundation.org/WDHD-2013-Final-Publication.pdf |
21 | Kaseb AO, Abaza YM, Roses RE (2013). Multidisciplinary management of hepatocellular carcinoma. Recent Results Cancer Res, 190, 247-59. DOI |
22 | Forner A, Llovet JM, Bruix J (2012). Hepatocellular carcinoma. Lancet, 379, 1245-55. DOI ScienceOn |
23 | Grieco A, Pompili M, Caminiti G, et al (2005). Prognostic factors for survival in patients with earlyintermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut, 54, 411-8. DOI ScienceOn |
24 | Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N (2012). Multidisciplinary management of hepatocellular carcinoma. Clin Gastroenterol Hepatol, 10, 354-62. DOI ScienceOn |
25 | Bruix J, Sherman M, Llovet JM (2001). EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol, 35, 421-30. DOI ScienceOn |
26 | Abdel-Hamid NM, Nazmy MH, Mahmoud AW, Fawzy MA, Youssof M (2011). A survey on herbal management of hepatocellular carcinoma. World J Hepatol. 3, 175-83. DOI ScienceOn |
27 | Bruix J, Sherman M (2005) Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology, 42, 1208-36. DOI ScienceOn |
28 | Bruix J, Sherman M (2011). American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology, 53, 1020-2. DOI ScienceOn |
29 | Della Corte C, Colombo M (2012). Surveillance for hepatocellular carcinoma. Semin Oncol, 39, 384-98. DOI ScienceOn |
30 | Dogan E, Yalcin S, Koca D, Olmez A (2012). Clinicopathological characteristics of hepatocellular carcinoma in Turkey. Asian Pac J Cancer Prev, 13, 2985-90. 과학기술학회마을 DOI ScienceOn |
31 | Egyptian Ministry of Health. Egyptian Ministry of Health Annual Report (2007). Available from: http://www.mohp.gov.eg/Main.asp |
32 | Yeh C, Chen M, Lee W, Jeng L (2002). Prognostic factors of hepatic resection for hepatocellular carcinoma with cirrhosis: univariate and multivariate analysis. J Surg Oncol, 81, 195-02. DOI ScienceOn |
33 | Zekri AR, Hassan ZK, Bahnassy AA, et al (2012). Molecular prognostic profile of Egyptian HCC cases infected with hepatitis C virus. Asian Pac J Cancer Prev, 3, 5433-8. 과학기술학회마을 DOI ScienceOn |
34 | Freedman LS, Edwards BK, Ries LAG (2006). Cancer incidence in four member countries (Cyprus, Egypt, Israel, and Jordan) of the middle east cancer consortium (MECC) compared with US SEER. Bethesda: National Cancer Institute; Available in: http://seer.cancer.gov/publications/mecc/mecc_monograph.pdf |